喜康生物(JHL Biotech)成立于2012年,由来自世界知名生物制药公司Genentech及Amgen的资深专业人士所领导,并集合了凯鹏华盈(KPCB)、红杉资本(Sequoia Capital)、Biomark Capital、台湾中华开发工业银行(CDIB)等顶级风险投资公司的资金支持。JHL的愿景是通过创新的制程,生产并提供全球患者价格更合理的生物制剂。JHL的使命是致力为全球合作伙伴提供生物制药领域的全方位解决方案。为实现企业愿景及使命,JHL将立足亚洲,以世界领先的制程开发及制造服务为全球公司提供质优价廉的生物医药。JHL目前致力于以最新制程与工程技术,简化原本相当复杂的哺乳类细胞培养制程,并降低生产成本。这些技术将应用在喜康生物位于亚洲,且符合美国、欧盟及国际医药法规协和会议(ICH)规范cGMP标准的世界级生产基地。喜康生技股份有限公司(喜康台湾)成立于2012年,目前已在台湾台北与中央研究院共建研发中心,并在新竹建立小型符合cGMP标准的生产基地。2013年4月已正式投入运营。喜康(武汉)生物医药有限公司于2013年2月在武汉光谷生物城成立,总投资额超过1亿美元。该项目的投资是目前国内生物药领域最大的投资。喜康武汉将采用GE医疗集团研发生产的模块化生物制药厂技术,建设全球首个KUBio抗体药物商业化生产基地,该基地严格按照cGMP标准设计建造,将成为中国第一家通过欧盟EMEA及美国FDA认证的生物制品生产基地,并成为国际领先的全球示范中心。喜康武汉的生产基地将拥有4个2000L发酵罐,并引进GE公司面向生物制药生产全过程的世界级技术。公司核心技术团队曾参与多个畅销抗体药物的研发与生产,拥有从细胞株筛选、工程优化和放大、品管体系的建立与管理、cGMP认证、生产设备管理、药物的临床开发等各个环节的核心技术和实际操作经验。喜康武汉将以世界领先的生产工艺及制造服务为全球患者研发生产高质量的治疗性抗体药物。主要研发方向为癌症和自身免疫类药物。同时,公司将与光谷生物城共建生物医药研发和生产公共服务平台,为全球生物制药企业提供专业的服务与支持。JHL Biotech (“JHL”) is a start-up company founded in 2012 with a vision of making biopharmaceuticals affordable and accessible to all patients through manufacturing innovation. Led by an experienced team of Genentech and Amgen veterans, and funded by top-tier venture capital firms including Kleiner Perkins Caufield & Byers (KPCB), Sequoia Capital, Biomark Capital and CDIB, JHL is uniquely positioned to deliver manufacturing solutions to its worldwide partners.To achieve this vision, JHL will provide world-class process development and manufacturing services in Asia to companies developing and commercializing high-quality, affordable biologic medicines. JHL is leveraging the latest process and engineering technologies to reduce the complexity and cost of mammalian cell culture manufacturing. These technologies will be incorporated into world-class biologics API manufacturing facilities in Asia that comply with US, EU and ICH cGMP regulations and guidelines.JHL Taiwan founded in 2012 and has operated since April, 2013. Cooperated with the Central Research Institute, JHL has built the R & D Centre in Taipei and established a small manufacturer which conforms to cGMP.JHL Wuhan founded in February, 2013 in Biolake, Wuhan. With a total investment of more than 100 million dollars, JHL Wuhan is the biggest investment in field of biological medicine in China.Using the technology of modular Biopharmaceutical manufacturer developed by GE Healthcare, JHL Wuhan will build the first global commercial manufacturer of antibody drugs, which is designed and constructed strictly in accordance with cGMP. It will be the first mainland-based manufacturer that achieves both EMEA certification and FDA certification as well as be a leading model for world.JHL Wuhan will own four 2000L Bioreactors and introduce the world’s leading technology of the whole production process which developed by GE. Our core technical team was involved in a series of research and production of the world’s best-selling antibody drugs. They are experienced in core technology and operation of cell line, process optimization and scale-up, establishment and management of quality control system, GMP verification, facility management and clinical drug development. JHL Wuhan will provide high-quality, affordable biologic medicines through world-class process development and manufacturing services. Our main research direction is cancer and immune medicines. In the same time, cooperating with Biolake, JHL Wuhan will build a public service platform for biopharmaceutical R&D and production in order to provide professional support and services to the global pharmaceutical enterprises.